Is Amyris stock a buy or sell?
The Amyris stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
What are analysts'target prices for Amyris'stock?
2 analysts have issued 12-month target prices for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 156.1% from the stock's current price. View Analyst Price Targets for Amyris.
What's happening with Amyris Inc's supply chain?
While the company faced supply chain troubles in the third quarter, it's taking steps to rectify the situation. Amyris is developing ingredient-production facilities in Brazil and Reno that are expected to begin operations in 2022.
Why did Amyris’s Q3 earnings miss estimates?
Amyris missed sales and earnings estimates. The company faces supply chain challenges. Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris ( NASDAQ:AMRS) reported disappointing third-quarter 2021 earnings results yesterday after the market closed.
See more
Is Amyris stock a good buy?
Amyris has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Is amyris a public company?
Amyris, Inc. is a synthetic biotechnology and renewable chemical company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets. Amyris, Inc....Amyris (company)TypePublicWebsitewww.amyris.com10 more rows
Will amyris go up?
The 7 analysts offering 12-month price forecasts for Amyris Inc have a median target of 9.00, with a high estimate of 22.00 and a low estimate of 2.50. The median estimate represents a +296.48% increase from the last price of 2.27.
Who owns Amyris stock?
Top 10 Owners of Amyris IncStockholderStakeShares ownedFarallon Capital Management LLC5.30%16,931,427The Vanguard Group, Inc.5.29%16,909,833BlackRock Fund Advisors3.38%10,807,917BlackRock Advisors LLC3.09%9,879,0046 more rows
Is amyris a good company?
Amyris is a fast paced, challenging, and fun company to work for. The research and development is cutting edge and products are scaled-up and moved into manufacturing with impressive speed. Overall, the employees are very collaborative and work well in teams.
What does amyris company do?
Amyris, Inc. produces and distributes chemical products. The Company serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets. Amyris serves customers worldwide.
Is amyris a good long term investment?
On average, Wall Street analysts predict that AMYRIS's share price could reach $20.13 by May 25, 2023. The average AMYRIS stock price prediction forecasts a potential upside of 705% from the current AMRS share price of $2.50.
Why Amyris could be the next Tesla?
Like Tesla, Amyris has a dominant lead in rapidly expanding mega-markets, with strong brands/superior new products based on science, patented technologies, processes, and a multiyear lead on the competition.
Does amyris pay dividends?
AMYRIS (NASDAQ: AMRS) does not pay a dividend.
Why did Amyris stock drop?
Amyris (AMRS) was impacted in Q1 2021 from a ~$327M loss due to change in fair value of debt. Revenue of $57.7M was a ~67% decline.
When did amyris go public?
Sep 28, 2010Amyris is registered under the ticker NASDAQ:AMRS . Their stock opened with $16.00 in its Sep 28, 2010 IPO.
Is amyris a startup?
But what is remarkable about the story, and not mentioned in the press release, is that 20 years ago Amyris Biotechnologies was not a cosmetics company, but a startup hailed as a vanguard in a biofuel revolution.
Is Amyris a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 1 hold rati...
When is Amyris' next earnings date?
Amyris is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Amyris .
How were Amyris' earnings last quarter?
Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.37) earnings per share...
When did Amyris' stock split? How did Amyris' stock split work?
Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned b...
What price target forecast have analysts set for AMRS?
5 brokerages have issued 1 year target prices for Amyris' stock. Their forecasts range from $2.50 to $30.00. On average, they anticipate Amyris' st...
Who are Amyris' key executives?
Amyris' management team includes the following people: Mr. John G. Melo , Pres, CEO & Director (Age 56, Pay $1.94M) ( LinkedIn Profile ) Mr. Her...
What is John Melo's approval rating as Amyris' CEO?
53 employees have rated Amyris CEO John Melo on Glassdoor.com . John Melo has an approval rating of 54% among Amyris' employees. This puts John Me...
Who are some of Amyris' key competitors?
Some companies that are related to Amyris include Marathon Petroleum (MPC) , Valero Energy (VLO) , Phillips 66 (PSX) , PBF Energy (PBF) , CVR...
What other stocks do shareholders of Amyris own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD)...
3.5 Analyst's Opinion
Is Amyris a buy right now?
Amyris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
How has Amyris' stock price been impacted by Coronavirus?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock. View analyst ratings for Amyris or view top-rated stocks.
When is Amyris' next earnings date?
Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRS stock has increased by 41.2% and is now trading at $4.18. View which stocks have been most impacted by COVID-19.
How were Amyris' earnings last quarter?
Amyris is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022. View our earnings forecast for Amyris.
When did Amyris' stock split? How did Amyris' stock split work?
Amyris, Inc. (NASDAQ:AMRS) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.04. The biotechnology company earned $47.90 million during the quarter, compared to analyst estimates of $64.21 million.
What guidance has Amyris issued on next quarter's earnings?
Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.
Causes for Concern
Amyris updated its FY 2021 earnings guidance on Monday, February, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340 M-.
Third Quarter 2021 Financial Results: A Positive Surprise?
The five key points that make me worrisome about Amyris are presented below.
Wall Street's Take
Amyris reported in its Q3 2021 financial results that "record Q3 underlying revenue of $48 million increased 40% continuing the year-over-year and sequential growth trajectory. Record consumer revenue of $23 million increased 89% versus Q3 2020".
TipRanks
Turning to Wall Street, Amyris has a Strong Buy consensus based on three Buys ratings. The average Amyris price target of $21.33 represents 296.5% upside potential.
How to buy shares in Amyris
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.
Buy Amyris shares from these brokerages
Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Is it a good time to buy Amyris stock?
Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Is Amyris stock undervalued or overvalued?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Have Amyris's shares ever split?
Valuing Amyris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amyris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amyris share price volatility
Amyris's shares were split on a 1:15 basis on 5 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amyris shares – just the quantity.
Amyris overview
Over the last 12 months, Amyris's shares have ranged in value from as little as $3.65 up to $23.42. A popular way to gauge a stock's volatility is its "beta".
AMRS earnings per share forecast
Amyris, Inc. , a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally.
AMRS revenue forecast
What is AMRS 's earnings per share in the next 3 years based on estimates from 3 analyst s?
AMRS revenue growth forecast
What is AMRS 's revenue in the next 3 years based on estimates from 5 analyst s?
Signals & Forecast
How is AMRS forecast to perform vs Specialty Chemicals companies and vs the US market?
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Amyris stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Amyris stock A Buy?
Amyris finds support from accumulated volume at $4.32 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Amyris
Amyris holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.
About Amyris
In the last 100 trades there were 29.13 million shares bought and 24.68 million shares sold. The last trade was done 29 days ago by Dutra Ana who bough 20 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
NASDAQ: AMRS
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What happened
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
So what
Failing to deliver on both the top and bottom lines, synthetic-biology specialist Amyris ( AMRS -3.63% ) reported disappointing third-quarter 2021 earnings results yesterday after the market closed.
Now what
Although the company reported a year-over-year sales increase of 39.7%, it didn't seem to be enough to satisfy investors' appetites. Like Wall Street analysts, investors were expecting the company to report more on the top line.
Premium Investing Services
While the company faced supply chain troubles in the third quarter, it's taking steps to rectify the situation. Amyris is developing ingredient-production facilities in Brazil and Reno that are expected to begin operations in 2022.
